Jefferies keeps Endo at buy

Endo Pharmaceuticals Holdings, Inc. was maintained by Jefferies & Co., Inc. analyst David Windley at a buy, with a lowered target price of $30 on news that Endo may have to pull its oxycodone ER product from the market while the court case is retried in the lower court. Jefferies lowered its 2006 and 2007 earnings-per-share estimates by 27 cents and 20 cents, respectively, to $1.52 and $1.75. Shares of the Chadds Ford, Pa., pharmaceutical company were down $1.33, or 4.98%, at $25.39 on volume of 3,042,155 shares versus the three-month running average of 1,410,320 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.